Search

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Community Letter: Update on LGMD programs SRP-9003, SRP-9004, SRP-9005
Roots of innovation: From science fairs to the leading edge of precision genetic medicine
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
Treatment Access
Sarepta Therapeutics anuncia la convocatoria de solicitudes para la 8ª edición anual de Route 79, el Programa de Becas de Duchenne
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments